What it is
Combining two checkpoint-blocking antibodies, anti-TIGIT and anti-PD-L1, can push the immune system to make 'non-exhausted' CD8+ T cells that keep fighting a tumour. This study works out the mechanism and finds the trigger is not the T cells themselves. Because anti-TIGIT only works when its tail (the Fc region) can bind immune cells, the authors looked at myeloid cells carrying Fc receptors and found that conventional dendritic cells were required for the therapy to work. In treated tumours, these dendritic cells took on an activated state, displaying more of the costimulatory signals (CD80, CD86, and PVR) that rouse T cells. The therapy-expanded T cells, in turn, switched on receptors (CD28, then CD226) that read those signals, and dendritic-cell-derived PVR drove them toward the non-exhausted state. Type I interferon, set off by the antibody's Fc engagement, sustained the whole loop, and supplying it externally rescued an otherwise inactive version of the combination.
Why it matters
Anti-TIGIT antibodies have given mixed clinical results, and finding they work through dendritic cells and Fc engagement could help explain that and guide the next ones. TIGIT was a hotly pursued immunotherapy target whose clinical results have been mixed, and much of the field assumed such antibodies act directly on T cells. Showing the response instead runs through a dendritic-cell costimulatory cascade, kept alive by type I interferon, reframes how to build and combine these drugs: preserve Fc activity, engage dendritic cells, and consider interferon where the response is weak.
Every metric behind this entry is listed, with its source, under Sources and data below.
Filed underCancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, T-cell and B-cell Immunology
